This site is intended for UK Healthcare professionals only

Are you a UK Healthcare professional?

We are unfortunately unable to allow patients to attend the Oncology Professional Care Show

If you would like more information on oncology, please refer to the NHS website.

Visit the NHS website?

Sidebar CTAs

Guardant Health

Guardant Health

Stand: C54
Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. 

The Guardant360 liquid biopsy comprehensive genomic profiling test is the leading, analytically, and clinically validated liquid biopsy assay that effectively detects the four main classes of genomic alterations in 74 well-documented cancer genes, thereby enabling clinicians to identify candidates for targeted therapies and to avoid treatments which are less likely to be effective. It is indicated for all advanced solid tumours, both in first line and at progression. Guardant360 includes most guideline recommended genomic biomarkers, in line with those included on the National Genomic Test Directory, and has a very fast turnaround time, with an average of 7 days from sample receipt in the laboratory to issuing of the report. The test is performed in a single CLIA certified and CAP and ISO15189 accredited central laboratory in Redwood City, California.

Since being introduced, Guardant360 has become widely adopted in clinical practice and there are now more than 260 peer-reviewed publications, over 60 of which describe the outcomes achieved when patients are treated in line with their molecular tumour profile identified through Guardant360. The test has been used by over 11,000 oncologists, with more than 250,000 tests performed to date.


505 Penobscot Drive
Redwood City
United Kingdom
Visit website

Contact Exhibitor

View all Exhibitors